vs
ANGIODYNAMICS INC（ANGO）与RESOURCES CONNECTION, INC.（RGP）财务数据对比。点击上方公司名可切换其他公司
RESOURCES CONNECTION, INC.的季度营收约是ANGIODYNAMICS INC的1.5倍（$117.7M vs $79.4M），ANGIODYNAMICS INC净利率更高（-8.0% vs -10.8%，领先2.8%），ANGIODYNAMICS INC同比增速更快（9.0% vs -19.2%），RESOURCES CONNECTION, INC.自由现金流更多（$15.6M vs $4.2M），过去两年ANGIODYNAMICS INC的营收复合增速更高（2.8% vs -11.8%）
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
RGP原名 Resources Global Professionals，是 Resources Connection, Inc. 的核心运营主体，面向全球客户提供多领域专业咨询服务，覆盖财务会计、信息管理、治理风险合规、人力资本、法务监管、企业咨询与重组、战略传播以及供应链管理等板块。
ANGO vs RGP — 直观对比
营收规模更大
RGP
是对方的1.5倍
$79.4M
营收增速更快
ANGO
高出28.2%
-19.2%
净利率更高
ANGO
高出2.8%
-10.8%
自由现金流更多
RGP
多$11.3M
$4.2M
两年增速更快
ANGO
近两年复合增速
-11.8%
损益表 — Q2 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $117.7M |
| 净利润 | $-6.3M | $-12.7M |
| 毛利率 | 56.4% | 37.1% |
| 营业利润率 | -7.7% | -10.3% |
| 净利率 | -8.0% | -10.8% |
| 营收同比 | 9.0% | -19.2% |
| 净利润同比 | 40.9% | 81.6% |
| 每股收益（稀释后） | $-0.15 | $-0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANGORGP
| Q4 25 | $79.4M | $117.7M | ||
| Q3 25 | $75.7M | $120.2M | ||
| Q2 25 | $80.2M | $139.3M | ||
| Q1 25 | $72.0M | $129.4M | ||
| Q4 24 | $72.8M | $145.6M | ||
| Q3 24 | $67.5M | $136.9M | ||
| Q2 24 | $71.0M | $148.2M | ||
| Q1 24 | $75.2M | $151.3M |
净利润ANGORGP
| Q4 25 | $-6.3M | $-12.7M | ||
| Q3 25 | $-10.9M | $-2.4M | ||
| Q2 25 | $-6.0M | $-73.3M | ||
| Q1 25 | $-4.4M | $-44.1M | ||
| Q4 24 | $-10.7M | $-68.7M | ||
| Q3 24 | $-12.8M | $-5.7M | ||
| Q2 24 | $-13.4M | $10.5M | ||
| Q1 24 | $-187.7M | $2.5M |
毛利率ANGORGP
| Q4 25 | 56.4% | 37.1% | ||
| Q3 25 | 55.3% | 39.5% | ||
| Q2 25 | 52.7% | 40.2% | ||
| Q1 25 | 54.0% | 35.1% | ||
| Q4 24 | 54.8% | 38.5% | ||
| Q3 24 | 54.4% | 36.5% | ||
| Q2 24 | 54.3% | 40.2% | ||
| Q1 24 | 47.7% | 37.0% |
营业利润率ANGORGP
| Q4 25 | -7.7% | -10.3% | ||
| Q3 25 | -14.1% | -1.7% | ||
| Q2 25 | -7.2% | -47.0% | ||
| Q1 25 | -13.9% | -38.4% | ||
| Q4 24 | -15.2% | -52.7% | ||
| Q3 24 | -19.4% | -3.5% | ||
| Q2 24 | -20.4% | 7.6% | ||
| Q1 24 | -265.9% | 2.8% |
净利率ANGORGP
| Q4 25 | -8.0% | -10.8% | ||
| Q3 25 | -14.4% | -2.0% | ||
| Q2 25 | -7.5% | -52.6% | ||
| Q1 25 | -6.1% | -34.0% | ||
| Q4 24 | -14.7% | -47.2% | ||
| Q3 24 | -19.0% | -4.2% | ||
| Q2 24 | -18.9% | 7.1% | ||
| Q1 24 | -249.7% | 1.7% |
每股收益（稀释后）ANGORGP
| Q4 25 | $-0.15 | $-0.38 | ||
| Q3 25 | $-0.26 | $-0.07 | ||
| Q2 25 | $-0.15 | $-2.21 | ||
| Q1 25 | $-0.11 | $-1.34 | ||
| Q4 24 | $-0.26 | $-2.08 | ||
| Q3 24 | $-0.31 | $-0.17 | ||
| Q2 24 | $-0.35 | $0.31 | ||
| Q1 24 | $-4.67 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.6M | $89.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $176.3M | $194.6M |
| 总资产 | $269.7M | $289.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANGORGP
| Q4 25 | $41.6M | $89.8M | ||
| Q3 25 | $38.8M | $77.5M | ||
| Q2 25 | $55.9M | $86.1M | ||
| Q1 25 | $44.8M | $72.5M | ||
| Q4 24 | $54.1M | $78.2M | ||
| Q3 24 | $55.0M | $89.6M | ||
| Q2 24 | $76.1M | $108.9M | ||
| Q1 24 | $78.5M | $113.8M |
总债务ANGORGP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | — | — |
股东权益ANGORGP
| Q4 25 | $176.3M | $194.6M | ||
| Q3 25 | $178.9M | $206.4M | ||
| Q2 25 | $183.0M | $207.1M | ||
| Q1 25 | $185.9M | $277.8M | ||
| Q4 24 | $186.8M | $325.7M | ||
| Q3 24 | $196.6M | $407.2M | ||
| Q2 24 | $205.6M | $418.8M | ||
| Q1 24 | $218.7M | $414.9M |
总资产ANGORGP
| Q4 25 | $269.7M | $289.3M | ||
| Q3 25 | $265.6M | $287.2M | ||
| Q2 25 | $280.1M | $304.7M | ||
| Q1 25 | $285.4M | $375.6M | ||
| Q4 24 | $291.6M | $424.9M | ||
| Q3 24 | $293.6M | $512.9M | ||
| Q2 24 | $317.7M | $510.9M | ||
| Q1 24 | $324.8M | $523.2M |
负债/权益比ANGORGP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.7M | $15.9M |
| 自由现金流经营现金流 - 资本支出 | $4.2M | $15.6M |
| 自由现金流率自由现金流/营收 | 5.3% | 13.2% |
| 资本支出强度资本支出/营收 | 0.5% | 0.3% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-9.3M | $24.3M |
8季度趋势，按日历期对齐
经营现金流ANGORGP
| Q4 25 | $4.7M | $15.9M | ||
| Q3 25 | $-15.9M | $-7.8M | ||
| Q2 25 | $18.8M | $16.8M | ||
| Q1 25 | $-13.2M | $659.0K | ||
| Q4 24 | $2.5M | $1.8M | ||
| Q3 24 | $-18.3M | $-309.0K | ||
| Q2 24 | $5.0M | $3.2M | ||
| Q1 24 | $-12.5M | $20.5M |
自由现金流ANGORGP
| Q4 25 | $4.2M | $15.6M | ||
| Q3 25 | $-16.6M | $-8.0M | ||
| Q2 25 | $18.0M | $16.5M | ||
| Q1 25 | $-15.0M | $238.0K | ||
| Q4 24 | $1.7M | $61.0K | ||
| Q3 24 | $-19.3M | $-575.0K | ||
| Q2 24 | $4.4M | $3.0M | ||
| Q1 24 | $-13.1M | $20.4M |
自由现金流率ANGORGP
| Q4 25 | 5.3% | 13.2% | ||
| Q3 25 | -22.0% | -6.6% | ||
| Q2 25 | 22.5% | 11.8% | ||
| Q1 25 | -20.8% | 0.2% | ||
| Q4 24 | 2.3% | 0.0% | ||
| Q3 24 | -28.7% | -0.4% | ||
| Q2 24 | 6.2% | 2.1% | ||
| Q1 24 | -17.5% | 13.5% |
资本支出强度ANGORGP
| Q4 25 | 0.5% | 0.3% | ||
| Q3 25 | 1.0% | 0.1% | ||
| Q2 25 | 1.0% | 0.2% | ||
| Q1 25 | 2.5% | 0.3% | ||
| Q4 24 | 1.1% | 1.2% | ||
| Q3 24 | 1.6% | 0.2% | ||
| Q2 24 | 0.8% | 0.1% | ||
| Q1 24 | 0.8% | 0.1% |
现金转化率ANGORGP
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.30× | ||
| Q1 24 | — | 8.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
RGP
| US | $93.7M | 80% |
| Non Us | $24.0M | 20% |
